Live Attenuated Influenza Vaccine (LAIV)

Brianne Murphy
CDC Liaison/Public Health Manager, AstraZeneca
National Adult and Influenza Immunization Summit May 11, 2017



FluMist Quadrivalent

- AstraZeneca continues to be committed to manufacturing and distributing Live Attenuated Influenza Vaccine (LAIV) for the 2017-2018 influenza season utilizing our replacement strain, A/H1N1pdm09/Slovenia, to meet the needs of markets in other countries.
- Due to the current ACIP interim recommendation for LAIV, AstraZeneca at this time will not announce the amount of LAIV that will be available in the US for the 2017-2018 season since the future ACIP recommendation is pendng.
- LAIV is an FDA-approved seasonal influenza vaccine and continues to be used in other countries.
- LAIV is an important flu vaccine option for HCPs and their appropriate patients ages 2-49 years old.
- AstraZeneca supports the CDC goal of increasing vaccination rates to the Healthy People 2020 goal of 70% for all age groups.

ACIP, Advisory Committee on Immunization Practices; FDA, Food and Drug Administration

Important Safety Information

FluMist® Quadrivalent (Influenza Vaccine Live, Intranasal)
Important Safety Information

FluMist® Quadrivalent (Influenza Vaccine Live, Intranasal) is a vaccine indicated for active immunization of persons 2-49 years of age for the prevention of influenza disease caused by influenza A subtype viruses and type B viruses contained in the vaccine. FluMist Quadrivalent is for intranasal administration only.

FluMist Quadrivalent is contraindicated in persons who have had a severe allergic reaction (e.g., anaphylaxis) to any vaccine component, including egg protein, or after a previous dose of any influenza vaccine, and in children and adolescents receiving concomitant aspirin or aspirin-containing therapy.

In clinical trials, the risks of hospitalization and wheezing were increased in children <24 months of age who received trivalent FluMist® (Influenza Vaccine Live, Intranasal). Children <5 years of age with recurrent wheezing and persons of any age with asthma may be at increased risk of wheezing following FluMist Quadrivalent administration. FluMist Quadrivalent has not been studied in persons with severe asthma or active wheezing.

ACIP, Advisory Committee on Immunization Practices; FDA, Food and Drug Administration

Important Safety Information

If Guillain-Barré syndrome has occurred within 6 weeks of any prior influenza vaccination, the decision to give FluMist Quadrivalent should be based on careful consideration of the potential benefits and risks. FluMist Quadrivalent has not been studied in immunocompromised persons. The safety of FluMist Quadrivalent in individuals with underlying medical conditions predisposing them to wild-type influenza infection complications has not been established. FluMist Quadrivalent may not protect all individuals receiving the vaccine.

The most common solicited adverse reactions (occurring ≥10% in vaccine recipients and at least 5% greater than in placebo) reported after FluMist were runny nose or nasal congestion in all persons 2-49 years, fever >100˚F in children 2-6 years, and sore throat in adults 18-49 years. Among children 2-17 years who received FluMist Quadrivalent, 32% reported runny nose or nasal congestion and 7% reported fever >100˚F. Among adults 18-49 years who received FluMist Quadrivalent, 44% reported runny nose or nasal congestion and 19% reported sore throat.

Please see http://www.azpicentral.com/flumistquadrivalent/flumistquadrivalent.pdf for full Prescribing Information for FluMist Quadrivalent, including Patient Information

ACIP, Advisory Committee on Immunization Practices; FDA, Food and Drug Administration

Confidentiality Notice

This file is private and may contain confidential and proprietary information. If you have received this file in error, please notify us and remove it from your system and note that you must not copy, distribute or take any action in reliance on it. Any unauthorized use or disclosure of the contents of this file is not permitted and may be unlawful. AstraZeneca PLC, 1 Francis Crick Avenue, Cambridge Biomedical Campus, Cambridge, CB2 0AA, UK, T: +44(0)203 749 5000, www.astrazeneca.com